This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Keratinocyte Growth Factor-2, KGF-2, Fibroblast Growth Factor-10, FGF-10
Description: Repifermin stimulates the growth of skin cells and other cells by mimicking the effects of the natural growth factor KGF2. This potentially leads to therapeutic effects in cases where skin and other tissue are damaged -- sores in the mouth, throat, and gastrointestinal tract induced by chemotherapy or the gastrointestinal tract in patients with ulcerative colitis, for example.
Deal Structure: Glaxo agreed to co-develop and co-market Repifermin when the drug reaches phase III trials.
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.
Pink Sheet HGS discontinues repifermin
Scrip Auxano Biologics Ltd.
Additional information available to subscribers only: